TY - CHAP
T1 - β-Blockers to Prevent Decompensation of Cirrhosis in Compensated Patients With Clinically Significant Portal Hypertension
AU - Villanueva, Càndid
AU - Tripathi, Dhiraj
AU - Rodrigues, Susana G.
AU - Torres, Ferran
AU - Ripoll, Cristina
AU - Bosch, Jaime
N1 - Funding Information:
Financial Support This study has been supported in part by grants from the Instituto de Salud Carlos III (EC08/00087, PI10/01552, PI13/02535, PS09/00485, PI14/00876, PI15/00066) and Stiftung fur Leberkrankenheit
Publisher Copyright:
© Springer Nature Switzerland AG 2022.
PY - 2022/10/19
Y1 - 2022/10/19
N2 - The progression of cirrhosis from the compensated stage to the development of decompensation determines a marked decline in life expectancy. Portal hypertension is the main determinant of the complications defining decompensation (variceal bleeding, ascites, encephalopathy). The development of clinically significant portal hypertension (CSPH, i.e., HVPG ≥10 mmHg) defines a substage of compensated cirrhosis, with a higher risk of decompensation. Non-selective β-blockers (NSBBs) decrease portal pressure in cirrhosis with CSPH. The efficacy of NSBBs to prevent first bleeding in patients with high-risk varices is well established. Recent data suggest that by decreasing portal pressure, NSBBs may also prevent other decompensating events such as ascites and may even improve survival in patients with compensated cirrhosis and CSPH. In this chapter we review the therapeutic potential of NSBBs in patients with compensated cirrhosis and already developed CSPH, indicating a high risk of decompensation.
AB - The progression of cirrhosis from the compensated stage to the development of decompensation determines a marked decline in life expectancy. Portal hypertension is the main determinant of the complications defining decompensation (variceal bleeding, ascites, encephalopathy). The development of clinically significant portal hypertension (CSPH, i.e., HVPG ≥10 mmHg) defines a substage of compensated cirrhosis, with a higher risk of decompensation. Non-selective β-blockers (NSBBs) decrease portal pressure in cirrhosis with CSPH. The efficacy of NSBBs to prevent first bleeding in patients with high-risk varices is well established. Recent data suggest that by decreasing portal pressure, NSBBs may also prevent other decompensating events such as ascites and may even improve survival in patients with compensated cirrhosis and CSPH. In this chapter we review the therapeutic potential of NSBBs in patients with compensated cirrhosis and already developed CSPH, indicating a high risk of decompensation.
KW - Clinically significant portal hypertension
KW - Compensated cirrhosis
KW - Prevention of decompensation of cirrhosis
KW - β-blockers
KW - Clinically significant portal hypertension
KW - Compensated cirrhosis
KW - Prevention of decompensation of cirrhosis
KW - β-blockers
KW - Clinically significant portal hypertension
KW - Compensated cirrhosis
KW - Prevention of decompensation of cirrhosis
KW - β-blockers
UR - http://www.scopus.com/inward/record.url?scp=85172138908&partnerID=8YFLogxK
U2 - 10.1007/978-3-031-08552-9_34
DO - 10.1007/978-3-031-08552-9_34
M3 - Chapter
AN - SCOPUS:85172138908
SN - 9783031085512
SP - 407
EP - 418
BT - Portal Hypertension VII
PB - Springer International Publishing AG
ER -
